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to assess the cost effectiveness of CML interventions were identified in MEDLINE 
and EMBASE. The studies were reviewed to map the method employed, how and why 
these approaches were selected, and lessons learned by the authors. Results: A 
total of unique CML models were reviewed. The large majority of these models were 
published in the last 10 years, with almost half being published in 2011. All but 1 of 
the models adopted a Markov structure, based around the following health states: 
chronic phase; accelerated phase; blast phase; and death. In line with best practice 
recommendations, over 75% of studies modeled progression and survival based on 
response to treatment. Extrapolation of trial data used a wide range of statistical 
models. Contrary to best practice recommendations, the fit of these models to the 
trial data and the validity of the extrapolation were not always tested. A variety of 
approaches were employed to estimate the health related quality of life associate 
with health states, including the direct valuation of health states, the use of stand-
ard health instruments (such as EQ5D), and mapping methods. ConClusions: 
Several approaches to the economic modeling of CML interventions were identified 
in the literature. A number of examples of good practice were identified, including 
the use of disease response outcomes when modeling progression and survival, and 
the systematic testing of the fit of survival distributions to trial data. Key challenges 
facing CML modeling are the validity of extrapolations of trial data given the long 
time periods over which these extrapolations are required, and the lack of data 
against which to validate them.
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objeCtives: The literature provides little guidance on statistical methods for esti-
mating parameters of Markov models using longitudinal data. We compared the 
commonly used naïve (based on raw data) and advanced approaches to estimate 
two model parameters: transition probabilities and hospitalisation rates. Both 
the naïve and advanced approaches were applied using data from the European 
Schizophrenia Cohort (EuroSC) to populate a Markov model in schizophre-
nia. Methods: EuroSC is a 2-year observational study of patients with schizo-
phrenia (n= 1,208), with 5 visits at 6-month intervals. Patients were classified into 
8 health states at each visit according to severity of symptoms assessed using the 
Positive and Negative Syndrome Scale (PANSS). For each health state, both model 
parameters (hospitalisation days and transition probabilities) were estimated 
based on raw data by pooling all time intervals (i.e. naïve approach). Similarly, 
for advanced methods, transition probabilities were estimated using multi-state 
models while hospitalisation days were estimated using two-part Generalised 
Estimating Equations (GEEs). Advanced methods adjusted for patient character-
istics and included random effects to account for repeated measures. Results: 
The naïve approach showed that the average number of hospitalisation days in 
a 6-month interval ranged from 4.20 in health state 1 to 19.43 in health state 8. 
Results from the two-part GEEs provided a range from 4.21 in health state 1 to 
14.7 in health state 8. GEEs tended to provide narrower confidence intervals. With 
regards to transition probabilities, differences between the naïve approach and the 
multi-state model were mostly seen in the second decimal place. ConClusions: 
While the naïve approach is frequently used for its simplicity, it has a number of 
shortcomings including: not accounting for repeated measures and not allowing 
for adjustment of patient characteristics. To increase the robustness of results, we 
recommend using statistical models that recognise and account for the unique 
distributional characteristics of data.
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objeCtives: Recent ISPOR Good practice guidelines as well as literature encourage 
to use a single distribution rather than the latent failure approach to model time to 
event for patient level simulation models with multiple competing outcomes. Aim 
was to apply the preferred method of a single distribution on time to event in combi-
nation with a multinomial distribution on type of event for parameterizing the pri-
mary tumor component of a patient level head and neck cancer model. Methods: 
Data on patients treated with radiation therapy as first line therapy for head and 
neck tumor at two university hospitals in The Netherlands between 25-02-1980– 
13-12-2010 was used (nUMCG= 277 & nVUMC= 736). Several distributions were 
tested for model fit, using QQ-plots, AIC, and simulated versus actual data plots 
to judge best fit. Covariates tested for inclusion were age, gender, tumor location 
dummies, nstage and tstage. The final model was applied in the patient simulation 
model. Multinomial regression with the same covariates and time of event added 
as a covariate was applied on type of event, distinguishing death, loco regional 
recurrence and metastasis as events. All analyses were performed in R. Results: 
The LogNormal distribution showed best fit. The final model had the following 
coefficients for the location parameter (se in brackets): Intercept, 8.2 (0.38), Age 
-0.026 (0.0053), Tstage -0.38 ( 0.062), Nstage -0.21 (0.076), Locd1 -0.91 (0.22) , Locd2 
-0.28 (0.15), Locd3 -0.72 (0.22). Locd refers to location dummies. The estimated 
value for Log(sd) was -0.44 (0.038). The multinomial model had age, tstage and 
time of event as significant covariates ConClusions: A disadvantage of this 
method is that a single distribution has to be fit to a time of event which is the 
result of different interacting stochastic processes. The resulting distributions 
showed acceptable fit and could be implemented straightforwardly in the patient 
level simulation model.
length in Markov models. The benefits of half-cycle correction has been widely 
published in the international literature. We measured the importance of half-cycle 
correction in the models submitted to the Hungarian HTA Office. We examined 
when it is adequate to use half-cycle correction and how big role should it have in 
the process of modelling. Results: Our experience shows that only 11% of the sub-
mitted models incorporated half-cycle correction. In more than half of these cases 
the value of the incremental cost-effectiveness ratio (ICER) changed by less than 1% 
when half-cycle correction was used compared to the base-case scenario. We also 
found the possibility that in some cases the added benefit of half-cycle correction 
is not considerable. ConClusions: The necessity of using half-cycle correction is 
essential in models, when the cycle length is half year or longer and if the number 
of the cycles of the models is less than 200. In most cases the half-cycle correction 
results in only a little change in the cost-effectiveness ratio of the submitted models, 
therefore half-cycle correction should be executed carefully.
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objeCtives: Randomized controlled clinical trials are the gold standard for deter-
mining causal inference. However, trials are expensive, and the results can be 
difficult to interpret. Our objective was to evaluate methods for clinical trial simu-
lation to understand how the simulation approach can be used for improved trial 
planning and interpretation of trial results. Our primary focus was trials of type 2 
diabetes and cardiovascular disease. Methods: We systematically searched the 
MEDLINE database for clinical trial simulation studies. We used the MeSH terms: 
Markov model, Markov chains, simulation, simulation model, microsimulation, 
computer model, and required type 2 diabetes mellitus and cardiovascular dis-
eases. We restricted the search to studies of humans published in English and 
found 92 publications. We also considered innovative clinical trial simulation 
methods from other areas to gain context. Results: A number of established 
techniques — notably, the Archimedes Model, Markov models, and observational 
analyses— are used for clinical trial simulation. Markov model-based simulations 
are widely employed, but have structural limitations with regard to the physiologi-
cal detail they can capture (e.g. multiple comorbidities). Retrospective, observa-
tional methods for clinical trial simulation are gaining utility as more databases 
become available. However, observational methods remain vulnerable to unknown 
biases. Finally, large-scale simulation models (such as the Archimedes model), with 
physiological underpinnings, provide accurate and clinically detailed trial simula-
tions. These models are used to simulate trials of therapies not yet marketed, or to 
forecast late stage trials. Model-based simulations require validations to ensure 
accuracy. ConClusions: Clinical trial simulation is an increasingly powerful 
tool, complementing real-world clinical trials. Large scale simulation modeling 
has been shown to be valuable for estimating and interpreting clinical findings. 
Recent studies suggest that future developments will leverage both large-scale 
simulation models and increasingly rich real-world evidence.
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objeCtives: New treatments registered in mCRPC are expected to alter the way 
patients are currently treated. It is hence essential for developers of any new treat-
ment not only to position it within the current therapeutic landscape, but also to 
anticipate what this landscape will resemble at time of launch. To address this issue, 
we developed a modeling tool that recast a new treatment’s value into the evolving 
therapeutic landscape. Methods: We conducted a literature review of existing 
health economic models in mCRPC, including recent HTA reports and conference 
abstracts. Technical and contextual elements were leveraged to build a flexible pro-
totype economic model for new treatments. The model encompasses disease man-
agement from asymptomatic mCRPC to patient’s death. It aims at describing the 
future management of mCRPC in including the current way patients are treated and 
the following innovative features: flexibility to alter the target population definition 
and size and to add new therapies. New therapies’ effectiveness and their expected 
positioning within the treatment pathway of mCRPC patients are assessed through 
the model. Results: We have created a dynamic prototype model to position new 
options in the current and future therapeutic landscape for treatment of mCRPC 
in Europe. Economic models identified in literature were addressing specific reim-
bursement questions and were not flexible enough to be re-used for our purpose of 
assessing therapeutic landscape evolution. However, some technical elements on 
costs and effectiveness could be leveraged for our model. The tool itself enabled to 
identify information gaps: epidemiology and real-life data were missing for some 
new treatments. These could be simulated and introduced in our easily-actualizable 
tool. ConClusions: An actualizable modeling and simulation tool was developed 
in mCRPC. This tool enables dynamic identification of the best public health and 
economic outcomes out of a new potential therapeutic alternative.
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objeCtives: To describe the methods adopted by economic models of CML inter-
ventions, assess their strengths and limitations, and develop best practice recom-
mendations. Methods: Examples of different economic modeling approaches used 
